External controls can augment low populations in rare disease trials

Retrieved on: 2023-11-27 15:56:39

Tags for this article:

Pharmaceutical industry

Food and Drug Administration

Clinical research

Drug discovery

Design of experiments

Click the tags to see associated articles and topics

External controls can augment low populations in rare disease trials. View article details on hiswai:

Excerpt

The gold standard of business intelligence. Find out more. Related Company Profiles. Merck & Co Inc · AstraZeneca Plc · GSK plc · Merck KGaA · ICON ...

Article found on: www.clinicaltrialsarena.com

View Original Article